The $4 Billion ADC Bet That Just Hit a Wall

But the FDA has been tightening the screws. The agency's 2025 draft guidance made it clear: single-arm trials (studies without a comparison group) are no longer the default ticket to accelerated approval. They're still acceptable in certain situations, like rare cancers or ethically constrained settings where randomizing patients would be impractical. For everything else, the FDA now prefers randomized trials with a proper control group.

The IDeate-Lung01 study was a Phase 2 trial. Mid-stage, no comparator arm. For a drug targeting a relatively common cancer like SCLC, the FDA apparently decided that wasn't compelling enough.

This Isn't Even the First Stumble

Reuters reported that ifinatamab deruxtecan's withdrawal was actually the second time a partnered cancer therapy under the Daiichi Sankyo/Merck deal had its U.S. application pulled. Two withdrawals from one mega-deal is not a great look, especially when the partnership was supposed to cement both companies as leaders in the ADC space.

That said, Wall Street didn't exactly panic. RBC Capital Markets called the withdrawal an "incremental negative setback" for Merck, noting that investors are still focused on other ADC assets in the broader portfolio.

The consensus? A program-specific delay, not a death blow to the ADC category. But that framing might be too generous.

The Real Story: FDA Is Rewriting the ADC Playbook

This withdrawal isn't just about one drug. It's a signal flare for an entire class of medicines.

ADCs have been biotech's hottest trend for the past three years. The premise is brilliant, and drugs like Enhertu have already proven the concept works. But the regulatory strategy behind many ADC programs has relied on a familiar formula: run a single-arm Phase 2 trial, show impressive response rates, file for accelerated approval, and figure out the confirmatory trial later.

The FDA is now saying: that playbook is expired.

The agency's updated framework demands that confirmatory trials be underway before accelerated approval is granted, not just planned on a slide deck. Enrollment should have started. Target completion dates should be realistic. And sponsors need to submit 180-day progress reports on those studies, turning what used to be a loose handshake into an ongoing audit.

For ADC developers, this changes the math. You can't just sprint to a Phase 2 readout and race to the FDA anymore. You need your Phase 3 engine running before you file, which means more money, more planning, and more risk upfront. Companies that built their timelines around the old approach may find themselves stuck in regulatory limbo.

Who Should Be Worried?

Any ADC sponsor banking on a single-arm Phase 2 study for accelerated approval should be paying very close attention. The FDA isn't saying ADCs can't use the fast lane; it's saying the on-ramp just got a lot steeper.

The companies most exposed are the ones targeting larger cancer populations (where the FDA will almost certainly demand randomized data) with programs that don't yet have confirmatory trials actively enrolling. If your confirmatory study is still in the "we'll start it after approval" phase, the ifinatamab story is your cautionary tale.

For Daiichi Sankyo and Merck specifically, the path forward likely means going back to the data. A larger, randomized trial could eventually support a new filing, but that takes years and significant additional investment on top of the billions already committed.

The Bottom Line

The FDA didn't reject ifinatamab deruxtecan. Technically, the companies withdrew before the agency had to. But the message was unmistakable: show up with stronger evidence, or don't show up at all.

In a sector where accelerated approval has been the cornerstone of commercial strategy, that's not just a regulatory footnote. It's a paradigm shift. The ADC gold rush isn't over, but the rules of the game just changed, and plenty of companies haven't gotten the memo yet.

The Rare Disease Drug That's Fixing Hearts Nobody Knew Were Breaking

BridgeBio's BBP-418 didn't just slow decline in a rare muscular dystrophy trial; it pushed cardiac biomarkers back toward healthy levels. With an FDA decision weeks away, these results could rewrite the playbook for a disease with zero approved treatments.